The Bronowski Institute runs a clinic in Woodend, Victoria. We have provided the Purpose and Objectives of the Clinic, as well as information on our staff there.
Contact details of the Institute and the Location of the Clinic.
Consistent with the charter of the Bronowski Institute of Behavioural Neuroscience the staff of the Bronowski Clinic is devoted to disseminating their knowledge and experience to improve the quality of life in people with Parkinson’s disease. To achieve this we provide or are developing the following professional support for medical doctors, clinicians and health professionals in their routine practice of treating this disorder.
To Provide professional advice on strategic light as an adjunctive treatment in Parkinson’s disease. Factors such as time, frequency and duration of treatment as well as crucial drug combinations and total drug burden that patients can tolerate. Critical adjuvant drug therapies and methods for titrating and titrating withdrawal strategies when using light as a parallel treatment.
To provide information as to the drugs and doses of drugs which interfere with the therapeutic effect of the light used in photopharmacological approach.
To provide advice as to the best management practices for the comorbidities of anxiety, depression and insomnia as a parallel when implementing the photopharmacological approach to treating Parkinson’s disease.
To advise as to the features and effects of light overdosing and provide a profile and consequences of light and drug overdosing in sensitive patients.
To provide a strategy for treating drug overdosing phenomena with strategic drug titration withdrawal strategies that will negate the need for invasive forms of surgical intervention.
To develop a Clinician’s Manual describing the key elements in using the photopharmacological method to safely and effectively treat Parkinson’s disease and its comorbidities.
To provide a description for a long term method for the application of the Photopharmacological approach to slow or stop the progressive degeneration of the disease.
A Chronology of Formal Scientific Publications and Presentations to Learned Scientific Societies Regarding Light as a Therapeutic and the Circadian System in the Aetiology and Treatment of Parkinson’s Disease
A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease.
Willis GL, Armstrong SM
Physiol. Behav. 66 (5):785-95, 1999.
Therapeutic effects of bright light therapy in Parkinson’s disease: A series of case reports.
Willis, G.L. and McLennan, C.A.
Melatonin and Biological Rhythms Symposium, Australian Chronobiology Society, Adelaide, South Australia, August 21-23, p.015, 2001.
Principles emerging from the clinical use of bright light therapy as the fundamental ingredient in treatment strategies for Parkinson’s disease: an update.
Willis, GL and Turner, EJD
Australian Chronobiology Society Conference, Melbourne, Victoria p14, 2006.
The Role of Psychologists in the Assessment and Treatment of Parkinson’s disease: Returning Quality of Life to the Elderly with Neuropsychiatric Disorders”,
Australian Psychological Society, Psychology and Aging Interest Group, October, 2007
Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study.
Willis GL, Turner EJ.
Chronobiol. Int. 2007; 24 (3):521-37.
The therapeutic effect of monochromatic blue light on the features of Parkinson’s disease using a quasi-blind strategy.
Australian Chronobiology Society-5th Annual Meeting, Sydney, Australia, p. 20b, 2008.
Parkinson’s disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process.
Rev. Neurosci. 2008; 19 (4-5):245-316. Review.
Can long-term light therapy slow the progressive degeneration of Parkinson’s disease?
Willis, GL, Moore C Armstrong SM
Australian Chronobiology Society-6th Annual Meeting, Melbourne, Australia, p. 23, 2009.
New Vistas on Parkinson’s disease.
Willis GL, Armstrong SM
Eur. J. Neurol. 2010 Apr;17 (4):519-20. doi: 10.1111/j.1468-1331.2009.02852.x. Epub 2009 Nov 18. No abstract available.
The therapeutic effect of strategic long term light therapy in Parkinson’s disease,
GL Willis, GL, Moore C, Armstrong, SM,
Australian Chronobiology Society-8th Annual Meeting, Melbourne, Australia, p. 6, 2011.
A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease.
Willis GL, Moore C, Armstrong SM
Rev. Neurosci. 2012 Mar 1; 23 (2):199-226. doi: 10.1515/revneuro-2011-0072.
Breaking away from dopamine deficiency: an essential new direction for Parkinson’s disease.
Willis GL, Moore C, Armstrong SM
Rev. Neurosci. 2012; 23 (4):403-28. doi: 10.1515/revneuro-2012-0037. Review.
The origins of the study of circadian involvement in neuropsychiatric disease.
Invited Plenary Lecture, Australian Chronobiology Society, Adelaide, S.S., August 13-14, 2017.
Circadian system – A novel diagnostic and therapeutic target in Parkinson’s disease?
Videnovic A, Willis GL
Mov. Disord. 2016 Mar; 31 (3):260-9. doi: 10.1002/mds.26509. Epub 2016 Jan 30. Review.
Emerging preclinical interest concerning the role of circadian function in Parkinson’s disease.
Willis GL, Freelance CB
Brain. Res. 2018 Jan 1; 1678: 203-213. doi: 10.1016/j.brainres.2017.09.027. Epub 2017 Sep 25. Review.
The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: an open label, retrospective, longitudinal study.
Martino JK, Freelance CB, Willis GL
Sleep Med. 2018 Apr; 44: 24-31. doi: 10.1016/j.sleep.2018.01.001. Epub 2018 Jan 31.
(Refereed scientific journals are in bold, abbreviated and underlined; Presentations to Learned Societies are in bold.)